Glucagon-like peptide-1 receptor agonists, weight loss, and gastric emptying: have I gut news for you.
作者信息
Jalleh Ryan J, Rayner Christopher K, Jones Karen L, Horowitz Michael
机构信息
Adelaide Medical School, The University of Adelaide, Adelaide, Australia.
Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia.
出版信息
Obesity (Silver Spring). 2022 Aug;30(8):1533-1534. doi: 10.1002/oby.23525.
Abstract
摘要
相似文献
1
Glucagon-like peptide-1 receptor agonists, weight loss, and gastric emptying: have I gut news for you.胰高血糖素样肽-1受体激动剂、体重减轻与胃排空：我有重要消息要告诉你。
Obesity (Silver Spring). 2022 Aug;30(8):1533-1534. doi: 10.1002/oby.23525.
2
Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying.胰高血糖素样肽-1受体激动剂与胃排空的恰当测量
Diabetes Obes Metab. 2020 Dec;22(12):2504-2506. doi: 10.1111/dom.14166. Epub 2020 Sep 3.
3
Trust the Gold Standard: All Glucagon-like Peptide-1 Receptor Agonists Can Delay Gastric Emptying.信赖金标准：所有胰高血糖素样肽-1受体激动剂均可延缓胃排空。
Anesthesiology. 2024 Jan 1;140(1):178-180. doi: 10.1097/ALN.0000000000004752.
4
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.红霉素可拮抗胰高血糖素样肽1引起的胃排空减速，并在健康受试者中揭示其促胰岛素分泌作用。
Diabetes. 2005 Jul;54(7):2212-8. doi: 10.2337/diabetes.54.7.2212.
5
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.液体试验餐后的胃排空、葡萄糖反应及胰岛素分泌：外源性胰高血糖素样肽-1（GLP-1）-（7-36）酰胺对2型（非胰岛素依赖型）糖尿病患者的影响
J Clin Endocrinol Metab. 1996 Jan;81(1):327-32. doi: 10.1210/jcem.81.1.8550773.
6
Accurate Measurements of Gastric Emptying and Gastrointestinal Symptoms in the Evaluation of Glucagon-like Peptide-1 Receptor Agonists.在胰高血糖素样肽-1受体激动剂评估中对胃排空和胃肠道症状的准确测量。
Ann Intern Med. 2023 Nov;176(11):1542-1543. doi: 10.7326/M23-2019. Epub 2023 Nov 7.
7
Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.葡萄糖摄入后内源性胰高血糖素样肽-1对胰岛激素释放和胃排空的调节作用。
J Clin Endocrinol Metab. 2008 Dec;93(12):4909-16. doi: 10.1210/jc.2008-0605. Epub 2008 Sep 30.
8
Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.静脉注射胰高血糖素样肽-1可有效抑制大鼠的食物摄入、假饲和胃排空。
Am J Physiol Regul Integr Comp Physiol. 2005 Jun;288(6):R1695-706. doi: 10.1152/ajpregu.00870.2004. Epub 2005 Feb 17.
9
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.在健康人体中，胰高血糖素样肽1对胃排空的抑制作用超过其促胰岛素分泌作用。
Am J Physiol. 1997 Nov;273(5):E981-8. doi: 10.1152/ajpendo.1997.273.5.E981.
10
Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.胰高血糖素样肽 1 受体延长和间断刺激对胃排空和血糖的比较影响。
Diabetes. 2014 Feb;63(2):785-90. doi: 10.2337/db13-0893. Epub 2013 Oct 2.
引用本文的文献
1
Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.经内镜袖状胃切除术的 57 例成人患者中胰高血糖素样肽 1 受体激动剂安全续贯应用：病例系列研究
Obes Surg. 2024 Jul;34(7):2369-2374. doi: 10.1007/s11695-024-07278-2. Epub 2024 May 16.
2
Newer pharmacological interventions directed at gut hormones for obesity.针对肥胖的新型肠道激素药理学干预措施。
Br J Pharmacol. 2024 Apr;181(8):1153-1164. doi: 10.1111/bph.16278. Epub 2023 Nov 30.
本文引用的文献
1
Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.利拉鲁肽对肥胖患者胃肠功能和体重的影响：一项随机临床和药物基因组学试验。
Obesity (Silver Spring). 2022 Aug;30(8):1608-1620. doi: 10.1002/oby.23481.
2
Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution.利西那肽对健康受试者和 2 型糖尿病患者能量摄入的急性影响：与胃排空和胃内分布的关系。
Nutrients. 2020 Jul 1;12(7):1962. doi: 10.3390/nu12071962.
3
Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations.艾塞那肽每周一次可减缓稳态浓度下健康超重者的固体和液体胃排空。
Diabetes Obes Metab. 2020 May;22(5):788-797. doi: 10.1111/dom.13956. Epub 2020 Jan 28.
4
Gastric Emptying in Patients With Well-Controlled Type 2 Diabetes Compared With Young and Older Control Subjects Without Diabetes.胃排空在血糖控制良好的 2 型糖尿病患者与年轻和老年非糖尿病对照者中的比较。
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3311-3319. doi: 10.1210/jc.2018-02736.
5
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.艾塞那肽对2型糖尿病患者胃排空的影响及其与餐后血糖的关系
Regul Pept. 2008 Nov 29;151(1-3):123-9. doi: 10.1016/j.regpep.2008.07.003. Epub 2008 Jul 16.
Zotero 插件